Testing Drugs For Resistant TB Seen As Prelude To Trials In Wider Population
Executive Summary
A Phase II trial of Johnson & Johnson's investigational tuberculosis drug TMC207 is highlighted in a June 4 New England Journal of Medicine editorial by NIAID's Cliffton Barry, not only for its positive results, but for its contribution to encouraging trial designs that could facilitate TB drug development
You may also be interested in...
FDA Encourages TB Drug Development But Wary Of Promoting Resistance
FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented
FDA Encourages TB Drug Development But Wary Of Promoting Resistance
FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented
Tuberculosis Trial Design: FDA/Company Endpoint Talks Go Public At Cmte.
The approval pathway for drugs to treat multi-drug resistant tuberculosis became somewhat clearer for sponsors as FDA's Anti-Infective Drugs Advisory Committee weighed in on clinical trial endpoints at a June 3 meeting